View this email in your browser

New Potential Antisense Drug for DM1

Researchers from Isis Pharmaceuticals collaborated with university teams from across North America to test out what could be the next generation of antisense drugs targeting myotonic dystrophy type 1 (DM1). As our community knows, the potential therapy currently in a phase I/II clinical trial, ISIS-DMPKRx, is also an antisense drug. To read the full story click here

Updates on Research: Report from the 2015 MDF Annual Conference

At MDF's annual conference in September, we heard from four of the newest MDF-funded Fellows, and from three pharmaceutical companies involved in early stage drug development for myotonic dystrophy. Read more here.

Grandparents Campaign a Great Success

MDF's third annual Grandparents Campaign was a great success!  Over ninety people donated more than $39,000 for myotonic dystrophy research and support. We thank all of you who supported these loving grandparents who are creating a brighter future for their grandchildren. Read more here

Next Month: Celebrate Caregivers!

November is National Family Caregivers Month. MDF is honoring the hard work of our DM caregivers with a series of events throughout the month. Click here to learn more and to access helpful caregiver resources.
Join us in celebrating National Family Caregivers Month by participating in this webinar on November 23rd. 

Upcoming Support Group Meetings:
10/22 - Seattle, WA
10/29 - Caregivers (virtual)
11/3 - Ottawa, Canada
11/7 - Indianapolis, IN
11/14 - Tampa, FL



Click here to tell us how you did on the first MDF Congressional Call-In
Join the Community! Follow us: 

Toll free (US only): (888) 968-6642 
Phone: (415) 800-7777

unsubscribe from this list    update subscription preferences